Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Azenta, Inc.AZTA · Entity 4724 | Director | August 08, 2023 | August 09, 2023 |
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | Director | May 07, 2026 | May 11, 2026 |
| GMR Solutions Inc.GMRS · Entity 5222 | Director | August 26, 2026 | August 28, 2026 |
| HAEMONETICS CORPHAE · Entity 3953 | Director | July 24, 2026 | July 28, 2026 |
| Synchrony FinancialSYF · Entity 3184 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Azenta, Inc.
Report date August 08, 2023 · Filed August 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,134 |
Reported balance
After 2023-08-08 transaction · row 1
1 source rowRow 1 · 2023-08-08 · Grant · Disposed 18,766 · Balance 41,134 F1: The sales reported on this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2022.
BOSTON SCIENTIFIC CORP
Report date May 07, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,934 |
Reported balance
After 2026-05-07 transaction · row 1
1 source rowRow 1 · 2026-05-07 · Grant · Acquired 3,800 · Balance 27,934 F1: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.
GMR Solutions Inc.
Report date August 26, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 976 |
Reported balance
After 2026-08-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-26 · Grant · Acquired 976 · Balance 976 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer Class A common stock ("Class A Common Stock"). The RSUs will be settled in either Class A Common Stock or cash (or a combination thereof) at the Issuer's discretion. F2: These RSUs vest on the earlier of (i) July 1, 2027 and (ii) the first regularly scheduled annual meeting of the stockholders of the Issuer following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer Class A common stock ("Class A Common Stock"). The RSUs will be settled in either Class A Common Stock or cash (or a combination thereof) at the Issuer's discretion.
F2: These RSUs vest on the earlier of (i) July 1, 2027 and (ii) the first regularly scheduled annual meeting of the stockholders of the Issuer following the date of grant.
HAEMONETICS CORP
Report date July 24, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,911 |
Reported balance
After 2026-07-24 transaction · row 1
1 source rowRow 1 · 2026-07-24 · Grant · Acquired 2,538 · Balance 21,911 F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Synchrony Financial
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,087 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 846 · Balance 33,087 F1: Represents restricted stock units that will vest in full on September 30, 2027. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that will vest in full on September 30, 2027. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PAREXEL INTERNATIONAL CORP
Report date September 29, 2017 · Filed October 04, 2017
Section 16 reporting ended · disclosed 2017-10-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-09-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-09-29 · Disposition to issuer · Disposed 49,534 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017 (the "Merger Agreement"), whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of the Issuer's common stock were automatically cancelled and converted into the right to receive $88.10 per share in cash without interest (the "Merger Consideration"). F2: Ellen Zane holds 22,984 shares of Common Stock directly and 22,550 shares of Common Stock indirectly through a charitable trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017 (the "Merger Agreement"), whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of the Issuer's common stock were automatically cancelled and converted into the right to receive $88.10 per share in cash without interest (the "Merger Consideration").
F2: Ellen Zane holds 22,984 shares of Common Stock directly and 22,550 shares of Common Stock indirectly through a charitable trust.
Press Ganey Holdings, Inc.
Report date October 21, 2016 · Filed October 25, 2016
Section 16 reporting ended · disclosed 2016-10-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-10-21 transaction · row 1
1 source rowRow 1 · 2016-10-21 · Disposition to issuer · Disposed 28,770 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 3, 2026 00:09 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 846 | $70.97 | $60,040.62 |
DisclosureSEC source: 0001369850-26-000010 · wk-form4_1790971770.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,087 F1 · date: Represents restricted stock units that will vest in full on September 30, 2027. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 17:14 UTC | GMR Solutions Inc. GMRS · Entity 5222 | GrantRestricted Stock Units · Derivative | 976 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-103325 · tm2624312-3_4seq1.xml · derivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 976 Underlying: Class A Common Stock · 976 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer Class A common stock ("Class A Common Stock"). The RSUs will be settled in either Class A Common Stock or cash (or a combination thereof) at the Issuer's discretion. F2 · derivative.exercise_date: These RSUs vest on the earlier of (i) July 1, 2027 and (ii) the first regularly scheduled annual meeting of the stockholders of the Issuer following the date of grant. F2 · derivative.expiration_date: These RSUs vest on the earlier of (i) July 1, 2027 and (ii) the first regularly scheduled annual meeting of the stockholders of the Issuer following the date of grant. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:49 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 14 | $80.75 | $1,130.50 |
DisclosureSEC source: 0001369850-26-000009 · wk-form4_1787172566.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,241 F1 · shares: Represents dividend equivalent units accrued on August 17, 2026 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on August 17, 2026 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F2 · balance_after: Balance adjusted to account for rounding of fractional shares over time. Read SEC document |
| July 24, 2026 Filed Jul 28, 2026 21:02 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,538 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000313143-26-000111 · form4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,911 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 20:32 UTC | GMR Solutions Inc. GMRS · Entity 5222 | GrantRestricted Stock Units · Derivative | 9,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-080779 · tm2619689-4_4seq1.xml · derivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,972 Underlying: Class A Common Stock · 9,972 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer Class A common stock ("Class A Common Stock"). The RSUs will be settled in either Class A Common Stock or cash (or a combination thereof) at the Issuer's discretion. F2 · derivative.exercise_date: These RSUs vest on July 1, 2027. F2 · derivative.expiration_date: These RSUs vest on July 1, 2027. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:08 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 789 | $76.05 | $60,003.45 |
DisclosureSEC source: 0001369850-26-000007 · wk-form4_1783022906.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,229 F1 · date: Represents restricted stock units that will vest in full on June 30, 2027. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:23 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 14 | $71.38 | $999.32 |
DisclosureSEC source: 0001369850-26-000005 · wk-form4_1779222227.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,440 F1 · shares: Represents dividend equivalent units accrued on May 15, 2026 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on May 15, 2026 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| May 07, 2026 Filed May 11, 2026 20:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 3,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005115 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,934 F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 21:44 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 883 | $68.02 | $60,061.66 |
DisclosureSEC source: 0001369850-26-000003 · wk-form4_1775166272.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,426 F1 · date: Represents restricted stock units that will vest in full on March 31, 2027. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:05 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 14 | $72.31 | $1,012.34 |
DisclosureSEC source: 0001369850-26-000002 · wk-form4_1771535102.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,543 F1 · shares: Represents dividend equivalent units accrued on February 17, 2026 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on February 17, 2026 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:54 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 660 | $83.43 | $55,063.80 |
DisclosureSEC source: 0001369850-26-000001 · wk-form4_1767653641.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,529 F1 · date: Represents restricted stock units that will vest in full on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 22:12 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 15 | $70.47 | $1,057.05 |
DisclosureSEC source: 0001369850-25-000005 · wk-form4_1763590348.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,869 F1 · shares: Represents dividend equivalent units accrued on November 17, 2025 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on November 17, 2025 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| November 06, 2025 Filed Nov 6, 2025 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 12,891 | $98.28 | $1,266,977.75 |
DisclosureSEC source: 0001225208-25-008997 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,134 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on July 25, 2025. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $97.89 to $98.65, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 20:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | OtherCommon Stock | 12,891 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-008842 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,025 F1 · kind: This Form 4 reflects that the sales by the reporting person of an aggregate of 12,891 shares reported on a Form 4 filed on October 28, 2025 were effected by mistake. On October 29, 2025 these shares were rescinded through the broker's error account and therefore are deemed to have never occurred. F1 · price: This Form 4 reflects that the sales by the reporting person of an aggregate of 12,891 shares reported on a Form 4 filed on October 28, 2025 were effected by mistake. On October 29, 2025 these shares were rescinded through the broker's error account and therefore are deemed to have never occurred. Read SEC document |
| October 28, 2025 Filed Oct 28, 2025 21:44 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 2,901 | $102.24 | $296,598.82 |
DisclosureSEC source: 0001225208-25-008761 · doc4.xml · nonDerivative · entry 2 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,134 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on July 25, 2025. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $102.165 to $102.31, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 21:44 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 9,990 | $101.13 | $1,010,300.69 |
DisclosureSEC source: 0001225208-25-008761 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,035 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on July 25, 2025. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $100.57 to $101.405, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 22:20 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 775 | $71.05 | $55,063.75 |
DisclosureSEC source: 0001369850-25-000003 · wk-form4_1759443653.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,854 F1 · date: Represents restricted stock units that will vest in full on September 30, 2026. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:38 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 15 | $71.49 | $1,072.35 |
DisclosureSEC source: 0001369850-25-000002 · wk-form4_1755639529.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,079 F1 · shares: Represents dividend equivalent units accrued on August 15, 2025 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on August 15, 2025 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 20:36 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,693 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-019599 · form4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,373 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 21:01 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 825 | $66.74 | $55,060.50 |
DisclosureSEC source: 0001601712-25-000223 · wk-form4_1751490094.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,064 F1 · date: Represents restricted stock units that will vest in full on June 30, 2026. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:12 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 17 | $60.49 | $1,028.33 |
DisclosureSEC source: 0001601712-25-000190 · wk-form4_1747692720.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,239 F1 · shares: Represents dividend equivalent units accrued on May 15, 2025 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on May 15, 2025 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| May 08, 2025 Filed May 9, 2025 21:35 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 2,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004936 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,025 F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:11 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 1,039 | $52.94 | $55,004.66 |
DisclosureSEC source: 0001601712-25-000134 · wk-form4_1743624666.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,222 F1 · date: Represents restricted stock units that will vest in full on March 31, 2026. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| February 24, 2025 Filed Feb 24, 2025 21:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 13,586 | $104.23 | $1,416,133.99 |
DisclosureSEC source: 0001225208-25-002270 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,944 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 14, 2024. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $103.88 to $104.545, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:56 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 13 | $65.29 | $848.77 |
DisclosureSEC source: 0001601712-25-000076 · wk-form4_1740095784.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,183 F1 · shares: Represents dividend equivalent units accrued on February 18, 2025 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on February 18, 2025 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:11 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 635 | $65.01 | $41,281.35 |
DisclosureSEC source: 0001601712-25-000013 · wk-form4_1735938662.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,170 F1 · date: Represents restricted stock units that will vest in full on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 23:12 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 15 | $64.98 | $974.70 |
DisclosureSEC source: 0001601712-24-000374 · wk-form4_1732057913.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,535 F1 · shares: Represents dividend equivalent units accrued on November 15, 2024 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on November 15, 2024 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| September 30, 2024 Filed Oct 3, 2024 00:58 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 827 | $49.88 | $41,250.76 |
DisclosureSEC source: 0001601712-24-000323 · wk-form4_1727917088.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,520 F1 · date: Represents restricted stock units that will vest in full on September 30, 2025. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:21 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 23 | $45.89 | $1,055.47 |
DisclosureSEC source: 0001601712-24-000292 · wk-form4_1724102491.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,693 F1 · shares: Represents dividend equivalent units accrued on August 15, 2024 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on August 15, 2024 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 20:21 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,207 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-021033 · form4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,680 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 21:04 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 875 | $47.19 | $41,291.25 |
DisclosureSEC source: 0001601712-24-000233 · wk-form4_1719954246.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,670 F1 · date: Represents restricted stock units that will vest in full on June 30, 2025. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:48 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 26 | $44.14 | $1,147.64 |
DisclosureSEC source: 0001601712-24-000206 · wk-form4_1715978872.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,795 F1 · shares: Represents dividend equivalent units accrued on May 15, 2024 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on May 15, 2024 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| May 09, 2024 Filed May 13, 2024 20:38 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 2,901 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005973 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,530 F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 21:34 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 957 | $43.12 | $41,265.84 |
DisclosureSEC source: 0001601712-24-000138 · wk-form4_1712093679.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,769 F1 · date: Represents restricted stock units that will vest in full on March 31, 2025. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:19 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 33 | $39.85 | $1,315.05 |
DisclosureSEC source: 0001601712-24-000086 · wk-form4_1708467540.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,812 F1 · shares: Represents dividend equivalent units accrued on February 15, 2024 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on February 15, 2024 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 23:07 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 1,081 | $38.19 | $41,283.39 |
DisclosureSEC source: 0001601712-24-000015 · wk-form4_1704323236.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,779 F1 · date: Represents restricted stock units that will vest in full on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| November 09, 2023 Filed Nov 14, 2023 22:34 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 45 | $29.15 | $1,311.75 |
DisclosureSEC source: 0001601712-23-000296 · wk-form4_1700001249.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,698 F1 · shares: Represents dividend equivalent units accrued on November 9, 2023 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on November 9, 2023 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 21:23 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 1,350 | $30.57 | $41,269.50 |
DisclosureSEC source: 0001601712-23-000263 · wk-form4_1696368183.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,653 F1 · date: Represents restricted stock units that will vest in full on September 30, 2024. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 22:21 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 39 | $34.40 | $1,341.60 |
DisclosureSEC source: 0001601712-23-000238 · wk-form4_1692051659.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,303 F1 · shares: Represents dividend equivalent units accrued on August 10, 2023 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on August 10, 2023 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| August 08, 2023 Filed Aug 9, 2023 20:10 UTC | Azenta, Inc. AZTA · Entity 4724 | GrantCommon Stock | 18,766 | $55.78 | $1,046,767.48 |
DisclosureSEC source: 0001209191-23-045166 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,134 F1 · price: The sales reported on this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2022. Read SEC document |
| August 04, 2023 Filed Aug 8, 2023 20:38 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,226 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-022206 · form4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,473 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:17 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 1,217 | $33.92 | $41,280.64 |
DisclosureSEC source: 0001601712-23-000196 · wk-form4_1688591835.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,264 F1 · date: Represents restricted stock units that will vest in full on June 30, 2024. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:35 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 48 | $27.08 | $1,299.84 |
DisclosureSEC source: 0001601712-23-000156 · wk-form4_1684269316.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,047 F1 · shares: Represents dividend equivalent units accrued on May 12, 2023 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on May 12, 2023 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| May 04, 2023 Filed May 5, 2023 20:27 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 3,946 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005472 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,629 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:12 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 1,419 | $29.08 | $41,264.52 |
DisclosureSEC source: 0001601712-23-000112 · wf-form4_168063913097557.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,999 F1 · date: Represents restricted stock units that will vest in full on March 31, 2024. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:44 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 35 | $35.77 | $1,251.95 |
DisclosureSEC source: 0001601712-23-000055 · wf-form4_167710224992108.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,580 F1 · shares: Represents dividend equivalent units accrued on February 17, 2023 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on February 17, 2023 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:22 UTC | Azenta, Inc. AZTA · Entity 4724 | GrantCommon Stock | 3,604 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009729 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,900 F1 · price: Grant of unrestricted shares under the company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 21:18 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 1,256 | $32.86 | $41,272.16 |
DisclosureSEC source: 0001601712-23-000014 · wf-form4_167286707213163.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,545 F1 · date: Represents restricted stock units that will vest in full on December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 21:23 UTC | Synchrony Financial SYF · Entity 3184 | GrantDividend Equivalent Unit | 30 | $38.73 | $1,161.90 |
DisclosureSEC source: 0001601712-22-000260 · wf-form4_166854738936527.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,289 F1 · shares: Represents dividend equivalent units accrued on November 10, 2022 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. F1 · price: Represents dividend equivalent units accrued on November 10, 2022 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:44 UTC | Synchrony Financial SYF · Entity 3184 | GrantCommon Stock | 1,464 | $28.19 | $41,270.16 |
DisclosureSEC source: 0001601712-22-000239 · wf-form4_166491607805191.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,259 F1 · date: Represents restricted stock units that will vest in full on September 30, 2023. Each restricted stock unit represents a contingent right to receive one share of Synchrony Financial common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.